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Summary Topoisomerase II is a key target for many anti-cancer drugs used to treat breast cancer. In human
cells there are two closely related, but differentially expressed, topoisomerase II isoforms, designated
topoisomerase Ila and P. Here, we report the production of a new polyclonal antibody raised against a
fragment of the C-terminal domain of the 180 kDa form of topoisomerase II (the P isoform), which does not
cross-react with the 170 kDa form (the a isoform). Using this antibody, together with a polyclonal antibody
specific for the 170 kDa isoform of topoisomerase II, we have examined the relationship between the
sensitivity of a panel of human breast cancer cell lines to different classes of topoisomerase II inhibitors and
cellular levels of the topoisomerase IIa and P3 proteins. We found that sensitivity to amsacrine showed a
correlation with the level of expression of topoisomerase IIa protein, and that sensitivity to etoposide showed
a similar correlation with the level of expression of topoisomerase Ilp protein. There was also a relationship
between sensitivity of these cell lines to mitoxantrone and the cellular level of both isoforms of topoisomerase
II. No relationship was found between the level of mRNA for topoisomerase Ila or P, and either sensitivity of
breast cancer cell lines to topoisomerase II inhibitors or the level of topoisomerase II protein expression.
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Topoisomerase II is a key target for many anti-cancer drugs
used to treat cancer, including doxorubicin, epirubicin,
mitoxantrone and etoposide (reviewed in Liu, 1989; Osheroff
et al., 1991; Capranico and Zunino, 1992; Pommier, 1993).
DNA topoisomerase II is a nuclear enzyme which alters
DNA tertiary structure through transient double-stranded
breakage of the DNA backbone and subsequent passage of a
second intact DNA duplex through the break (reviewed in
Osheroff et al., 1991; Wang, 1985; Austin and Fisher, 1990;
Watt and Hickson, 1994). The aforementioned drugs, as well
as several other intercalating agents, including amsacrine
(Nelson et al., 1984), trap the enzyme in a covalently bound
reversible complex with DNA, termed the cleavable complex.
The stabilisation of this complex prevents religation of the
broken DNA and produces lesions which are thought to be
cytotoxic by virtue of their ability to inhibit the passage of
the replication fork. There is evidence that the cellular level
of topoisomerase II determines the extent of cleavable com-
plex formation after drug treatment and, therefore, the
degree of drug toxicity. Low levels of topoisomerase II are
associated with the induction of a reduced number of DNA
lesions and hence increased drug resistance (Beck et al., 1993;
Pommier, 1993). The converse relationship has been shown
in mutant cell lines hypersensitive to topoisomerase II
inhibitors (Davies et al., 1988) and also in testicular teratoma
cell lines compared with bladder cell lines (Fry et al., 1991).
There are two isoforms of topoisomerase II in mammalian
cells that are products of different genes (Drake et al., 1989;
Jenkins et al., 1992; Tan et al., 1992; Austin et al., 1993).
These isoforms are termed a (170 kDa form) and , ((180 kDa
form) and have different patterns of expression, suggesting
that they might perform different functions. The a isoform is
produced primarily in late S-phase and during the G2/M
phase of the cell cycle (Woessner et al., 1991), and is appar-
ently more sensitive to teniposide and merbarone than is the
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P isoform, at least in vitro (Drake, et al., 1989). The gene
encoding the a isoform has been mapped to chromosome
17q21-22 in humans (Tsai-Pflugfelder et al., 1988). The P
isoform is expressed throughout the cell cycle, with higher
levels seen in non-proliferating cells (Woessner et al., 1991)
and is encoded on chromosome 3p24 in humans (Jenkins et
al., 1992; Tan et al., 1992).
Drug resistance is a major clinical problem in the treat-
ment of solid tumours. Tumours often become resistant to
multiple, structurally unrelated drugs as a result of expres-
sion of the membrane efflux pump, P-glycoprotein (reviewed
in Bradley and Ling, 1994). This is the classical form of
multidrug resistance (MDR). However, atypical MDR, due
to altered topoisomerase II activity, has also been well
documented (Beck et al., 1987; Morrow and Cowan, 1990;
Patel and Fisher, 1993; reviewed in Beck, et al., 1993). It is
possible that tumour levels of topoisomerase II could
strongly influence whether a particular drug will be effective
in the treatment of that tumour.
To evaluate the potential contributions of the two isoforms
of topoisomerase II to the response of breast cancer cells to
topoisomerase II inhibitors, we have studied a panel of breast
cancer cell lines for sensitivity to different classes of
topoisomerase II inhibitors. Doxorubicin and mitoxantrone
were studied as representatives of the DNA intercalators,
although doxorubicin has a greater propensity to generate
free radicals than has mitoxantrone. Etoposide was studied
as a representative of the epipodophyllotoxins, a group of
non-intercalating topo II inhibitors. Amsacrine was used
because there is evidence that this drug is not an efficient
substrate for the P-glycoprotein, unlike the anthracyclines,
and is commonly used as a model topoisomerase II inhibitor
in vitro. To evaluate expression of topoisomerase II, a new
antibody specific for the topoisomerase IIP protein was
generated. The panel of breast cancer cell lines studied
included both oestrogen-positive and oestrogen-negative cell
lines, since it has been shown that oestrogen can enhance the
effects of topoisomerase II inhibitors in oestrogen-responsive
breast cancer cells (Zwelling et al., 1983; Epstein et al., 1988;
Epstein and Smith, 1988).Our results show that sensitivity to amsacrine is related to
the expression of the topoisomerase Ilo protein, while expres-
sion of topoisomerase IIP is related to the sensitivity of cells
to etoposide. Mitoxantrone sensitivity could be correlated
with expression of both topoisomerase II isoforms. Thus,
expression of different isoforms may be relevant to selection




The cell lines studied are listed in Table I. Cell lines were
maintained in RPMI-1640 supplemented with 2 mM L-
glutamine and 10% fetal calf serum. Cells were grown in a
humidified atmosphere containing 5% carbon dioxide at
37°C, and were regularly checked for mycoplasma con-
tamination using the mycotect assay (Gibco).
Drugs
Doxorubicin was supplied as a pure drug from Farmitalia
UK (St Albans, UK). A stock solution (2 mM) was made in
normal saline and stored at - 20°C. Mitoxantrone was a gift
from Dr LH Patterson, and was dissolved in phosphate-
buffered saline (PBS) and stored at - 20°C as a 10mm stock
solution. Amsacrine (m-AMSA), supplied by Parke-Davis
(MI, USA), was dissolved in dimethyl sulphoxide (DMSO)
and stored as a 5 mM stock solution in 50% DMSO at
- 20°C. Clinical grade etoposide (VP16) was obtained from
Bristol Laboratories (Bedford, OH, USA) and stored at 4°C.
Chlorambucil (Wellcome) was freshly prepared in alkaline
ethanol (10 mM sodium hydroxide in ethanol). Mitomycin C
was obtained from Sigma (Dorset, UK) and stored as a stock
solution of 3.3 mg ml-' in DMSO. Doxorubicin and chlor-
ambucil were diluted to working concentrations in normal
saline. All other drugs were diluted in PBS.
Overexpression andpurification of a C-terminalfragment of
human topoisomerase IIP protein
A cDNA fragment representing residues Pro-1441 to the
natural stop codon of the topoisomerase Ip protein (Jenkins
et al., 1992) was amplified using the polymerase chain reac-
tion (PCR). The oligonucleotides incorporated 5' and 3' XhoI
sites for cloning into pET14b (Invitrogen). This vector con-
tains an oligopeptide leader sequence upstream on the XhoI
site which includes a stretch of six histidine residues. The
645 bp PCR product was purified, digested with XhoI and
was cloned into XhoI-digested pET14b. For expression in
Escherichia coli, the resultant plasmid, designated pET-psub
was transformed into strain BL21 (DE3), which co-expresses
the T7 RNA polymerase. Transformants were grown to
OD650 0.4 before addition of isopropyl ,B-D-thiogalacto-
pyranoside (IPTG) (0.4 mM) to induce expression from the
T7 promoter in pET14b. After a further 2 h of growth, the
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bacteria were lysed, and the lysate was separated on a nickel-
chelate column (Invitrogen), according to the manufacturer's
instructions. The 215 amino acid topoisomerase IIP fragment,
containing the oligohistidine tag at the N-terminus, was
retained by the column, while virtually all host proteins were
not. The topoisomerase Ilp fragment was eluted with 1 M
immidazole buffer, dialysed against PBS and stored at
-80°C.
Antibodies
The purified C-terminal fragment of topoisomerase pro-
tein was used to immunise two rabbits (six injections of
100 sg protein per injection). Serum from one of these rab-
bits recognised a single 180 kDa protein on Western blots of
HeLa cell nuclear extracts and was stored at -80'C. For
detection of topoisomerase IIa protein, a commercial rabbit
polyclonal antibody, termed CRB was used (supplied by
Cambridge Research Biochemicals). This antibody has been
shown in previous studies to be specific for the ot isoform
(Smith and Makinson, 1989; Wells et al., 1994).
Whole cell extraction oftopoisomerase II
Whole cell extracts were made using the method of Drake et
al. (1989). Briefly, cells were trypsinised, washed in PBS
containing 1 mM phenylmethylsulphonyl fluoride (PMSF),
1 mM benzamidine, 10 g ml-' soybean trypsin inhibitor and
50 lg ml-' leupeptin and then lysed in 1 ml of 2% sodium
dodecyl sulphate (SDS) in the same buffer at 65°C for 5 min.
The DNA was disrupted by passing the sample through a 23
gauge needle a number of times. Samples were stored at
-200C.
Nuclear extraction oftopoisomerase II
Nuclear extracts were prepared using the method of Glisson
et al. (1986). Cell pellets (- Il07-108 cells) were washed in
PBS, resuspended in TMN buffer (10 mM Tris-HCl, ph 7.5/
1.5 mm magnesium chloride/ 10 mM sodium chloride/ 1 mM
PMSF/ 1% Nonidet P-40) and held on ice for 45 min. Nuclei
were pelleted at 600 g for 10min, resuspended in 2 ml
TKMC buffer (50 mM Tris-HCI, pH 7.5/25 mM potassium
chloride/ 3 mM magnesium chloride/ 2 mM calcium chloride/
1 mM PMSF) and layered onto a cushion of 0.6 M sucrose in
the same buffer. The nuclei were pelleted at 2000 g for
10min, washed with 2 ml TKM buffer (5 mM Tris-HCl,
pH 7.5/ 5 mm magnesium chloride/ 25 mM potassium chlo-
ride/ 1 mM PMSF) containing 0.25 M sucrose and repelleted
at 2000g for 10 min. The resulting pellet was resuspended in
0.15 ml TKM buffer plus 15 ll 0.2 M EDTA and two
volumes of buffer D (80 mM Tris-HCl, pH 7.5/ 1 mM DTT/
2 mM EDTA/ 0.53 M sodium chloride/ 20% glycerol/ 1 mM
P-glycerophosphate/ 2 1sg ml- ' leupeptin/ 2tLg ml -' pepstatin
A/2 ;g ml-' aprotinin) and left on ice for 30 min. Debris was
removed by centrifugation at high speed in an eppendorf
microfuge for 25 min. Protein concentration was measured
by the method of Bradford (1976) and samples stored at
Table I Characteristics of breast cancer cell lines
Doubling Percentage ofcells Seeding
Cell lines Characteristics times (h) in S-phase densityper well
ZR75 ER + ve, PGR + ve 35 15 10 000
MCF7wt ER + ve 44 24 5000
T47D ER + ve 31 17 10 000
MDA 231 ER-ve, EGFR + ve 27 27 5 000
SKBr3 ER-ve, amplified 22 28 5000
topoisomerase Ila
and erbB2
MDA 468 ER-ve, 27 28 5 000
amplified EGFR
MCF7adr ER-ve, MDR 25 50 5000
ER, oestrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor;
MDR, multidrug resistance.A Topoisomerase 11 isoforms in breast cancer
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20C after diluting 50:50 in sample buffer (62.5 mm Tris-
HCI, pH 6.8/ 10% glycerol/ 2% SDS/ 5% 2-mercapto-
ethanol).
Chemosensitivity assays
Suspensions of the exponentially growing cells were obtained
from each line and plated in 96-well dishes in 180flI of fresh
medium at a seeding density which would not reach
confluence over 4 days (Table I). To this medium was added
20 glI of 10 x concentrated drug. Following 4 days con-
tinuous drug exposure, MTT [3-(4,5-dimethylthiazoll-2-yl) -
2,5-diphenyltetrazolium bromide] was added to a final con-
centration of 0.4 mg ml and the incubation continued at
37°C for 4 h. Plates of cells were inverted to remove medium,
and the formazan crystals were solubilised by adding 100til
DMSO to cells plus 25 Il glycine buffer (0.1 M glycine/0. 1 M
sodium chloride/pH 10.5). Absorbency was read at 540 nm
using a microtitre plate reader.
Each determination was in quadruplicate and each experi-
ment was repeated at least three times. IC50 values were
generated using Deltasoft software (Biometallics, Princeton,
USA). The IC50 is the concentration of drug required to
reduce absorbency to 50% of that obtained for untreated
cells.
Western blotting
Nuclear extracts were diluted to equal protein concentrations
(100 mgml-') in sample buffer and whole cell extracts were
diluted to equal cell numbers (usually 2 x 106 cells ml-').
Samples of 50 ilI were loaded per well and were separated by
the discontinuous polyacrylamide gel method of Laemmli
(1970). Proteins were electrophoresed through the stacking
gel at 30 mA per gel and through the 7.5% separating gel at
50 mA per gel. Proteins were transblotted onto Hybond ECL
at 30 V overnight and detected using the ECL (Enhanced
Chemiluminescence) system (Pharmacia). Signal intensities
were quantified by laser scanning densitometry. Molecular
weight estimations were carried out by comparison with
molecular weight standards (myosin, 200 kDa; phosphorylase
b, 97.4 kDa; bovine serum albumin, 69 kDa; ovalbumin,
46 kDa; carbonic anhydrase, 30 kDa).
Estimation ofdoubling times
The doubling times of the cell lines were calculated using the
MTT assay. Cells were seeded at very low density in a
number of 96-well plates. A plate was read at daily intervals
and absorbency was converted to cell number using a stan-
dard curve of cell numbers against absorbency which was
constructed for each cell line.
Estimation ofS-phasefraction
The percentage of dividing cells in S-phase was determined
using propidium iodide staining. Briefly, washed cells were
fixed in ice-cold 70% ethanol for 30min. The ethanol was
washed away before addition of 100itgml-' RNAase and
incubation at 37°C for 20 min. The cells were washed with
PBS and resuspended in propidium iodide (50 jig ml-')
before analysis by flow cytometry. For cells which were
particularly clumped, the nuclei were isolated by washing in
0.1% Triton X100 for 0 min at room temperature before
fixing in ethanol.
Preparation ofRNA
Total RNA was prepared from cell lines by the single-step
method described by Chomczynski and Sacchi (1987). Before
use in RNAase protection assays, the integrity of each RNA
preparation was assessed by running the samples on a I %
agarose gel.
RNAaseprotection assays
The topoisomerase a and 1B probes were prepared as des-
cribed by Jenkins et al. (1992) and Davies et al. (1993)
respectively. All radiolabelled antisense transcripts were syn-
thesised in vitro using T3 RNA polymerase and [a-32P]CTP,
by the method outlined in Ausubel et al. (1989). The
topoisomerase IIa plasmid was linearised with EcoRI before
antisense transcript synthesis and produced a 215 bp pro-
tected fragment. The topoisomerase II,B plasmid was
linearised with BamHI and produced two protected frag-
ments of 228 and 296bp. In each reaction an internal
loading control of an antisense transcript to glyceraldyhyde-
3-phosphate dehydrogenase (GAPDH) was used. This probe
was digested with HindlIl and produced a 120 bp protected fragment. Each gel lane was loaded with 10 fig of total RNA.
The conditions for annealing and digesting of the RNA-
RNA hybrids were as described by Jenkins et al. (1992).
Results
Drug sensitivityprofiles
Sensitivity to five different anti-cancer drugs was studied in a
panel of breast cancer cell lines. In addition to the
topoisomerase II inhibitors, amsacrine, doxorubicin, mitox-
antrone and etoposide, one non-topoisomerase II inhibitor
was studied. The alkylating agent chlorambucil was included
to determine whether the sensitivity of these cell lines to
multiple drugs was likely to be mediated via one or more
common mechanisms (e.g. susceptibility to apoptosis). The
doxorubicin-resistant MCF7adr cell line, derived after pro- longed exposure in vitro to doxorubicin, is many-fold resis-
tant to all classes of topoisomerase II inhibitors and ex-
presses a high level of P-glycoprotein (Batist et al., 1986).
This cell line was included in the study for comparative
purposes. When cell lines were ranked in order of sensitivity
to amsacrine, it was found that the ranking for other
topoisomerase II inhibitors did not follow the same pattern
(Table II). For example, cell line ZR75 was 4-fold more
resistant than SKBr3 cells to amsacrine, but was equally
sensitive to doxorubicin. Similarly T47D was only 2-fold
more resistant than MCF7 cells to amsacrine, but was six
times more resistant to mitoxantrone.
The detection oftopoisomerase IIP with a new, specific
antibody
A recombinant fragment of the C-terminal domain of
topoisomerase Ip protein was expressed in E. coli and
purified by affinity chromatography (Figure 1). This C-
Table II IC50values ( ± s.e.m.) for different drugs in a panel of breast cancer cell lines
Cell line
Drugs SK Br3 MCF7 T47D MDA 231 ZR75 MDA 468 MCF7adr
Amsacrine (nM) 153 ± 19 324 ± 55 534 ± 58 585 ± 95 635 ± 155 973 ± 96 6339 ± 811 Mitoxantrone (nM) 16 ± 4 7.2 ± 0.2 43 ± 6 55 ± 8 95 ± 24 58 ± 7 2631 ± 265 Etoposide(t4M) 0.6±0.05 0.4±0.06 0.6±0.1 0.9±0.1 1.0±0.2 0.8±0.1 54±3 Doxorubicin (nM) 72 ± 16 63 ± 8 127 ± 24 120 ± 3 69 ± 19 79 ± 5 20851 ± 2979 Chlorambucil IM) 151± 17 13 ± 2 44 2 80 ± 7 52 ± 8 17 ± 3 26 ± 6
Cells are presented in order of increasing resistance to amsacrine from left to right.Topolsomerase 11 isoforms In breastcancer
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terminal region was chosen as an immunogen because of the
lack of sequence conservation with the human ac isozyme.
The purified protein was used to raise an antiserum in rabbits
which was subsequently analysed by Western blotting. This
showed that the antiserum recognised a single 180 kDa pro-
tein in nuclear extracts from the HeLa cell line (Figure 2).
There was no evidence for degradation products of
topoisomerase IIP being recognised by this antiserum. The
180 kDa protein was present in whole-cell and nuclear ext-
racts, but not in cytosolic fractions (not shown). To further
authenticate the antiserum, Western blotting ofdrug-resistant
cell lines known to have down-regulation of topoisomerase
IIP protein was performed. For example, the antiserum
recognised a 180 kDa protein in HL60 cell extracts which
was far less abundant in extracts of a drug-resistant variant
of HL60, designated HL60-MX-2, which has previously been
shown to express low levels of topoisomerase II,B protein
(Harker et al., 1991). Moreover, the antibody detected a
protein of molecular weight larger than that recognised by
two different anti-topoisomerase IIax-specific antibodies. Con-
sistent with this, a mixture of anti-topoisomerase IIax and P
antibodies revealed two distinct immunoreactive bands of 170
and 180 kDa (data not shown).
Western blotting for topoisomerase Iloa and was carried
out on whole cell extracts from the six breast cancer cell lines
using the new anti-topoisomerase IIP antibody together with
a previously characterised anti-topoisomerase IoI antibody
(Smith and Makinson, 1989; Wells et al., 1994). Figures 3
and 4 show that expression of the topoisomerase IIax and P




lines, but that expression levels of the two isoforms were not
correlated either inversely or directly with each other (Table
III). This suggests that the two isoforms are regulated
independently in these cell lines.
Relationship between expression oftopoisomerase IIac and
proteins and drug sensitivity
To determine if a relationship exists between expression of
topoisomerase II isoforms and drug sensitivity, a quantitative
assessment of the level of topoisomerase IIcc and P protein
expression (by densitometric scanning of Western blots) was
performed and the results compared with IC,0 values for each
topoisomerase II inhibitor. In this panel of six breast cancer
cell lines, sensitivity to amsacrine correlated with levels of
topoisomerase lIoa protein expression, while sensitivity to
etoposide correlated with levels of topoisomerase IIP protein
expression (Table IV). Mitoxantrone sensitivity was cor-
related with expression of both topoisomerase llcx and
topoisomerase IIP. Thus, there was isoform specificity in the
correlation between levels of topoisomerase II expression and
sensitivity to different classes of topoisomerase II inhibitors.
Relationship between expression oftopoisomerase IIac and
proteins and the levels oftopoisomerase IIa and mRNAs
The topoisomerase IIa (single transcript) and topoisomerase
IIP (two alternately spliced transcripts) mRNAs could be
detected in all of the cell lines studied using the RNAase
protection assay (Figure 5). To study the relationship
between topoisomerase II mRNA and protein expression in
each cell line levels of topoisomerase Ila and topoisomerase
P1/P2 mRNAs were quantified by densitometric scanning of
RNAase protection assay autoradiograms and the values
standardised against GAPDH as a loading control (Table V).
There was no apparent correlation in this panel of cell lines
between mRNA and protein expression for either topo-
isomerase isoform. The S-phase fraction did not correlate
with topoisomerase 11a or P mRNA expression; however,
there was only a 2-fold variation in the percentage of cells in
S-phase in the six cell lines (range 14.9-28%; Table I). There
was also no correlation between mRNA expression level for






Figure 1 Purification of a C-terminal fragment of human
topoisomerase I1P protein. The proteins that bound to the nickel
chelate column and eluted with 1M immidazole were separated
on an SDS-polyacrylamide gel and stained with Coomassie blue.
Lane 1, purified topoisomerase I,B C-terminal fragment; lane 2,
molecular weight markers (sizes are indicated on the right in
kDa). In multiple preparations, the topoisomerase IIP fragment
always ran as two species of 34 kDa and 23 kDa, which were
shown by tryptic mapping to be derived from the same protein.
Figure 2 The anti-topoisomerase Ilp antibody recognises a single
180 kDa protein in HeLa cell nuclear extracts. A HeLa cell
nuclear extract was electrophoresed alongside radiolabelled
molecular weight standards (lane M) on a 9% SDS-poly-
acrylamide gel, transferred to Hybond-N, and the membrane was
exposed either to preimmune serum (lane 1) or to the anti-
topoisomerase P antibody (lane 2). Antibody detection was with
I'251]-protein A. Molecular weights are indicated on the left. The
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Figure 3 Quantification of topoisomerase lIa protein expression in breast cancer cell lines. A Western blot of whole cell extracts
from different breast cancer cell lines is shown (indicated below each lane). Extracts were loaded in order ofincreasing resistance to
amsacrine from left to right. The antibody used was CRB, which is specific for topoisomerase lha and detects a single 170 kDa





Figure 4 Quantification of topoisomerase IIP protein expression in breast cancer cell lines. A Western blot of whole cell extracts
from different breast cancer cell lines is shown (indicated below each lane). Extracts were loaded in order of increasing resistance to
amsacrine from left to right. The antibody used was the new rabbit polyclonal serum specific for topoisomerase I1p, which detects a
single 180 kDa protein. Antibody detection was with an ECL detection kit.
Table III Levels of topoisomerase II a and 13 protein
Cell line Absorbance a Rank ot Absorbance1 Rank1
SKBr3 1656 6 1202 5
MCF7 1086 5 1233 6
T47D 588 3 1188 4
MDA 231 724 4 304 1
ZR75 384 2 719 2
MDA 468 382 1 873 3
MCF7 adr 556 Not included 1118 Not included
Cells are ranked in order of increasing resistance to amsacrine.
Western blots from three experiments were scanned and the median
value taken.
Table IV Correlation oftopoisomerase II proteinexpression with IC50
values for selected drugs
r-values






a Significant, P< 0.05. NS, not significant.
Discussion
This study shows that there is a wide variation in sensitivity
to topoisomerase II inhibitors in different breast cancer cell
lines and that sensitivity to particular classes of inhibitor is
related to expression of one or other (or both) isoform of
topoisomerase II. We have shown that expression of the a
isoform correlates with amsacrine sensitivity, while expres-
sion of the P isoform correlates with etoposide sensitivity.
Sensitivity to mitoxantrone is related to expression of both
isoforms. There was no correlation between topoisomerase II
protein levels and sensitivity to the alkylating agent chloram-
bucil, suggesting that these cell lines do not have a common
mechanism underlying drug sensitivity that could explain the
relative sensitivity to topoisomerase II inhibitors. Our study
has also shown that the two isoforms are apparently not
co-ordinately expressed in breast cancer cell lines.
We have described the production of a new antibody that
specifically detects the 180 kDa topoisomerase I1p isoform.
This may prove useful in the assessment of topoisomerase I,B
expression in primary cancers. A number of anti-topo-
isomerase II antibodies have been described previously; how-
ever, many of these recognise either the a isoform alone or
both isoforms. In our study, where the two isoforms have
clearly been distinguished, the results indicate that both
isozymes are potential drug targets for at least some classes
of topoisomerase II inhibitor. We would suggest, therefore,
that the potential for each enzyme to act as a target for a
particular drug needs to be analysed separately.
There have been previous studies in which panels of cell
lines from a single tumour type have been analysed. For
example, in a panel of lung cancer cell lines, it was found
that topoisomerase II activity (presumably representing the
combined activity of the two topoisomerase II isoforms)
correlated with sensitivity to topoisomerase II inhibitors
(Kasahara et al., 1992). A similar conclusion was drawn by
Giaccone et al. (1992), using a different panel of lung cancer
cell lines. In a previous study, we showed that three cell lines
from testicular teratomas, which are well known to be highly
sensitive in vivo and in vitro to topoisomerase II inhibitors,
had higher topoisomerase II levels than cell lines derived
from bladder tumours, which are known to be only
moderately drug sensitive (Fry et al., 1991). However, the
antibody used in that previous study recognised only the
topoisomerase IIa protein. It should be noted that some
previous studies on drug resistant variants of human and
rodent cell lines have indicated that there is unlikely to be a
simple relationship between topoisomerase II isozyme expres-
sion and drug sensitivity. In certain cases this is likely to be aTopoisomerase II isoforms in breast cancer
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Table V Expression of topoisomerase 11 a and 13 mRNAs in breast cancer cell lines
Topoisomerase lIa Topoisomerase 1Ip1 Topoisomerase 11 P2
Cell line mRNA level mRNA level mRNA level
SKBr3 502 125 14
MCF7 1301 382 110
T47D 2917 973 182
MDA 231 2762 734 115
ZR75 714 385 563
MDA 468 527 225 40
Topoisomerase II mRNA levels are expressed in terms ofintegrated optical density values
from scanned autoradiograms, equalised in terms ofa GAPDH loadingcontrol, and ranked











Figure 5 Ribonuclease protection analysis of topoisomerase IIa
and topoisomerase I1p mRNA levels in human breast cancer cell
lines. An autoradiogram of an acrylamide gel showing the
mobility of RNA species protected from RNAase digestion.
Lanes: M, molecular weight standards, as indicated in base pairs
on the left; 1, SKBr3; 2, MCF7; 3, T47D; 4, MDA 231; 5, ZR75;
6, MDA 468. The positions of the topoisomerase IHa protected
fragment and the two alternately spliced topoisomerase Ilp trans-
cripts (P11 and P2) are indicated on the right. The GAPDH-
specific protection fragment is also indicated on the right. Den-
sitometric scanning of autoradiograms was conducted when each
signal was within the linear range for X-ray film.
reflection of the fact that non-topoisomerase II-mediated
mechanisms of resistance to topoisomerase II-targeting drugs
are important, such as the multidrug resistance associated
protein, MRP (Sneider et al., 1994).
There are several earlier studies that have shown a down-
regulation of topoisomerase Ila protein and/or mRNA levels
in cell lines with acquired resistance to a wide range of
topoisomerase II inhibitors (reviewed by Pommier, 1993;
Beck et al., 1993). However, only in a limited number of
studies has the relationship between intrinsic drug sensitivity
and topoisomerase II expression levels been analysed. The six
cells lines used in our study had not previously been exposed
to anti-cancer drugs in vitro and were derived from different
genetic backgrounds.
Our data are in agreement with those of Brown et al.
(1995) in showing that etoposide sensitivity appears to cor-
relate more closely with expression of the isoform than of
the a isoform. Moreover, although mitoxantrone sensitivity
correlated with expression of both topoisomerase II isoforms,
the observation that there is a relationship between topo-
isomerase Ip expression and mitoxantrone sensitivity is com-
patible with the finding that topoisomerase IIP expression is
reduced in mitoxantrone-resistant derivatives of HL60 cells
(Harker et al., 1991). These data suggest that mitoxantrone
may have some selectivity for topoisomerase Ilp, at least in
cell line models. Thus, the P isoform may be an important
target (or indeed the primary target) for two of the most
widely used classes of topoisomerase II inhibitors.
Sensitivity to doxorubicin showed no correlation with ex-
pression of either of the topoisomerase II isoforms, yet this
commonly used drug is known to be a topoisomerase II
inhibitor (Tewey et al., 1984). However, doxorubicin-induced
toxicity may be mediated via several other mechanisms, in-
cluding generation of free radicals, lipid peroxidation and
interactions with iron (Bachur et al., 1979; Tritton, 1991).
These non-topoisomerase II-dependent mechanisms may be
important for toxicity in the drug concentration range used
in this study. Indeed, high drug concentrations have been
found previously to be required to detect protein-associated
lesions (i.e. cleavable complex), compared with other topo-
isomerase II-targeting drugs (Zwelling et al., 1993). In a
panel of leukaemic cell lines doxorubicin resistance correlated
inversely with expression of the topoisomerase Ip protein
(Brown et al., 1995), a finding not seen with our panel of
breast cell lines.
Topoisomerase IIP has been reported not to be differenti-
ally regulated as cells traverse the cell cycle (Woessner et al.,
1991), although there is recent evidence from studies in pro-
liferating lymphocytes that this isoform is up-regulated dur-
ing commitment to proliferation (Kaufmann et al., 1994).
Because the isoform is expressed in a wide range of cell
types in vivo (unlike the a isoform; Sandri et al. a manuscript
in preparation), irrespective of their proliferation status, it is
not unreasonable to assume that topoisomerase II3 forms a
significant target for anti-cancer drug therapy (particularly
with the epipodophyllotoxins and mitoxantrone) in breast
cancer patients.
Our study analysed the relationship between mRNA and
protein expression for topoisomerase hIa and P. Our results
contrast with those for cell lines with acquired drug resis-
tance in vitro, which have shown that down-regulation of
topoisomerase Ila and P mRNA parallels protein down-
regulation in many cases (reviewed in Morrow and Cowan,
1990; Giaccone, et al., 1992; Beck et al., 1993). In the cell
lines studied here, which have not been exposed previously to
cytotoxic drugs, there was no correlation between levels of
mRNA and protein for either topoisomerase II isoform, in
agreement with the conclusions of Peters et al. (1994). Thus,
the relationship between mRNA level and protein expression
differed for each cell line, which suggests that post-
translational mechanisms may also be important in the
regulation of topoisomerase II protein levels. Our data also
indicate that attempts to quantify expression of
topoisomerase II mRNAs by PCR in human tumours might
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not form a useful guide in the selection of patients for
therapy, since mRNA levels are unlikely to reflect levels of
the corresponding protein.
Our study suggests that the level ofexpression of the a and
f isoforms influences sensitivity to different classes of
topoisomerase II-targeting drugs. A more definitive demons-
tration of this relationship will probably be forthcoming only
when the level of expression of the individual isozymes is
manipulated in human cells using antisense or overexpression
constructs. It will now be important to assess expression of
these isoforms in primary tumours, as it may be possible in
the future to select particular drugs for use in therapy based
upon topoisomerase II isoform expression in individual
tumours. Thus, attempts to select drugs for treatment of
individual patients rationally may improve their clinical res-
ponse.
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